Research output per year
Research output per year
Fingerprint
Dive into the research topics where Niels Viggo Jensen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 15 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots or
Research output
-
Real-world Treatment Patterns and Overall Survival in Locally Advanced and Metastatic Urothelial Tract Cancer Patients Treated with Chemotherapy in Denmark in the Preimmunotherapy Era: A Nationwide, Population-based Study
Omland, L. H., Lindberg, H., Carus, A., Als, A. B., Jensen, N. V., Taarnhøj, G. A., Trepiakas, R., Suetta, C., Omland, L. H. & Pappot, H., Feb 2021, In: European Urology Open Science. 24, p. 1-8Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile -
First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.
McDermott, D. F., Lee, J-L., Bjarnason, G. A., Larkin, J. M. G., Gafanov, R. A., Kochenderfer, M. D., Jensen, N. V., Donskov, F., Malik, J., Poprach, A., Tykodi, S. S., Gordoa, T. A., Cho, D. C., Geertsen, P. F., Duran, M. A. C., Simone, C. D., Du, X., Perini, R. F., Rodriguez-Lopez, K. & Atkins, M. B., 20. May 2020, In: Journal of Clinical Oncology. 38, Suppl. 15, 5069.Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
Open Access -
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
Donskov, F., Motzer, R. J., Voog, E., Hovey, E., Grüllich, C., Nott, L. M., Cuff, K., Gil, T., Jensen, N. V., Chevreau, C., Negrier, S., Depenbusch, R., Bergmann, L., Cornelio, I., Champsaur, A., Escudier, B., Pal, S., Powles, T. & Choueiri, T. K., Feb 2020, In: European Journal of Cancer. 126, p. 1-10Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile -
Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)
Holmsten, K., Jensen, N. V., Mouritsen, L. S., Jonsson, E., Mellnert, C., Agerbæk, M., Nilsson, C., Moe, M., Carus, A., Öfverholm, E., Lahdenperä, O., Brandberg, Y., Johansson, H., Hellström, M., Maase, H. V. D., Pappot, H. & Ullén, A., Mar 2020, In: European Journal of Cancer. 127, p. 173-182Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile -
A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1
Donskov, F., Jensen, N. V., Smidt-Hansen, T., Brøndum, L. & Geertsen, P., May 2018, In: Acta Oncologica. 57, 5, p. 589-594Research output: Contribution to journal › Journal article › Research › peer-review
Open AccessFile
Activities
-
European Cancer Congress
Niels Viggo Jensen (Participant)
28. Sep 2013 → 1. Oct 2013Activity: Attending an event › Conference organisation or participation
-
RADS - Rådet for Anvendelse af Dyr Sygehusmedicin (External organisation)
Niels Viggo Jensen (Member)
6. Sep 2013 → …Activity: Membership › Board duties in companies, associations, or public organisations
-
Annual Meeting of the American Society of Clinical Oncology
Niels Viggo Jensen (Participant)
31. May 2013 → 4. Jun 2013Activity: Attending an event › Conference organisation or participation
-
Dansk Selskab for Klinisk Onkologi
Niels Viggo Jensen (Participant)
11. Apr 2013 → 13. Apr 2013Activity: Attending an event › Conference organisation or participation
-
Dansk Renalcelle Cancer Gruppe - DARENCA (External organisation)
Niels Viggo Jensen (Member)
2013 → …Activity: Membership › Board duties in companies, associations, or public organisations